Servier Appoints MaSTherCell for the Development of its CAR-T Cell Therapy Manufacturing Platform - Seite 2
"This partnership will result in developing solutions for one of the biggest challenges to the ongoing development of the cell therapy sector. MaSTherCell has quickly built the most extensive CDMO experience in manufacturing and process industrialization development in the cell therapy industry," said Denis Bedoret, CBO at MaSTherCell. "This enables MaSTherCell to leverage that experience to deliver solutions to contribute to the Servier cell therapy pipeline. We will thus be able to directly contribute to delivery of life-saving cell therapy treatments to patients."
"The scale up of manufacturing for late scale clinical trials still remains one of the biggest industry-wide challenges in the cell therapy sector, and especially in a CAR-T field still in its infancy," said Marielle Anger-Leroy, Director of Biotechnology Industrial Development at Servier. "Being pioneers with these innovative therapies means that we have to find the best partners to maximize the chances of delivering these therapies to patients with few alternative options."
About Servier
Servier is an international pharmaceutical company governed by a foundation and headquartered in France. With a strong international presence in 148
countries and a turnover of 4 billion Euros in 2016, Servier employs over 21,000 people worldwide. Corporate growth is driven by Servier's constant search for innovation in five areas of
excellence: cardiovascular diseases, diabetes, cancers, immune-inflammatory diseases, and neurodegenerative diseases, as well as by its activities in high-quality generic drugs. Being
completely independent, the Group reinvests 25% of Servier's products turnover in research and development and uses all its profits for growth.
Lesen Sie auch
Becoming a key player in oncology is part of Servier's long-term strategy. Currently, there are nine molecular entities in clinical development in this area, targeting gastric and lung cancers and other solid tumors, as well as various leukemias and lymphomas. This portfolio of innovative cancer treatments is being developed with partners worldwide, and covers different cancer hallmarks and modalities, including cytotoxics, proapoptotics, targeted, immune and cellular therapies to deliver life-changing medicines to patients. For more information, visit www.servier.com.